La Merie Publishing: Market Research Reports

Competitor Analysis: Anti-Infective Peptides The present Competitive Intelligence Report about Anti-Infective Peptides used to treat bacterial, viral and ... with the project data to print or export an individual report. Anti-Bacterial Peptides Anti-bacterial peptides are used to treat infectious diseases such ...

Competitor Analysis: Cardiovascular Peptides The present Competitive Intelligence Report about Cardiovascular Peptides used to treat or prevcent heart failure, myocardial infarction, thrombosis, hypertension, peripheral vascular diseases, hemostasis and wound sealing provides a competitor evaluation in the ...

Competitor Analysis: Anti-Inflammatory Peptides The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under ...

Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins The present Competitive Intelligence Report about prophylaxis and therapy of Rabies ... virus infections as of September 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any ...

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes ...

Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors The present Competitive Intelligence Report about alpha1-proteinase inhibitors (alpha1-PI), alpha1-antitrypsin (AAT) and elastase inhibitors provides a competitor evaluation in the field of human ...

Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders This business ... regarding botulinum neurotoxin engineering, modification and manufacturing. Chances and challenges for the stakeholders in the botulinum neurotoxin market are evaluated. The market for botulinum neurotoxin ...

Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors The present Competitive Intelligence Reportabout phosphodiesterease 4 (PDE-4) Inhibitors provides a competitor evaluation in the field of mainly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4) as of June 2010. ...

Competitor Analysis: Kallikrein Inhibitors Bradykinin Receptor Antagonists The present Competitive Intelligence report aboutKallikrein Inhibitors Bradykinin Receptor Antagonists provides a competitor evaluation in the field of marketed and novel approaches for prophylaxis and treatment of hereditary ...

... lines), microorganism-based and others. Of the 140 clinical stage cancer vaccines, three were approved and are commercialized in the major ... . In addition, the report lists company-specific R&D pipelines of cancer vaccines. Competitor projects are listed in a tabular format providing information on: Drug ...

... and allow online work with the project data to print or export an individual report. With the approval and launch of next generation Her2 ... cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...

... Pipeline Analysis The report entitled Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis published in January 2014 is based on the evaluation of more ... arising from new site-specific and from polymer/nanoparticel-based conjugation systems and the most promising new payloads for ADCs. ...

... , Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, ...

... developments in the pipeline of inhibitors of the janus-associated kinase (JAK) and of spleen tyrosine kinase provides a competitor evaluation in the field of active ... ) are made up of a family of four cytoplasmic tyrosine kinases—JAK1, JAK2, JAK3, and TYK2—that play pivotal roles in the signaling pathways ...

... , proteins, peptides, vaccines and small molecules for prevention and treatment of Staphylococcus aureus infections. In addition, the report lists company-specific R&D pipelines of S. aureus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: Drug ...

... new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks. This report entitled The ... and pitfals in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products ...

... of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...

... and development of small molecule and siRNA/miRNA inhibitors of the Pim Kinases. In addition, the report lists company-specific R&D pipelines of Pim Kinase inhibitors. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...

... antibody inhibitors of the Wnt ligand or its receptors Frizzled and LRP5/6 in oncology. In addition, the report lists company-specific R&D pipelines of Wnt pathway inhibitors. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of ...

The present Competitive Intelligence report about Bruton’s Tyrosine Kinase (BTK) Inhibitorsprovides a competitor evaluation in the field of small molecule-based inhibitors of Bruton’s Tyrosine Kinase (BTK) for the treatment of B-cell related hematologic malign ancies and autoimmune diseases as of August 2013. ...

The present Competitive Intelligence report about Focal Adhesion Kinase (FAK) Inhibitors provides a competitor evaluation in the field of small molecule-based ... and development of selective and multi-target small molecule Focal Adhesion Kinase (FAK) inhibitors in oncology. In addition, the report lists company ...

The present Competitive Intelligence report about Anaplastic Lymphoma Kinase (ALK) Inhibitors provides a competitor evaluation in the field of small molecule and antibody-based inhibitors of Anaplastic Lymphoma Kinase (ALK) for the treatment of solid tumors as of August 2013. Purchase ...

The Competitive Intelligence report Smallpox Vaccines & Therapeutics as of August 2013 provides a competitor analysis in the development pipelines of novel vaccines and therapeutics for prophylaxis of Variola virus infection and treatment of smallpox. Purchase of the pdf report includes a 6-month online ...

The present Competitive Intelligence report about Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors provides a competitor evaluation in the field of small molecule ... that repair DNA damage. Despite the recent failure of Sanofi’s PARP inhibitor iniparib, presentation of results from clinical studies with other ...

... sources can be viewed and printed. Sales figures of major therapeutic proteins on the market are provided. An advanced search function allows to combine ... by e-mail within 24 hours after purchase. Benefits from the Protein Target & Pipeline Database: Intuitive use Designed for structured searches Focused ...

... /Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody therapy has spurred the discovery and development of efficacy ... with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information ...

The present Competitive Intelligence Report about Competitor Analysis: c-MET/HGF Inhibitors provides a competitor evaluation in the field of small molecule and ... HGF receptor) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF) for the treatment of solid tumors as of July 2013. Purchase of the ...

The Competitive Intelligence Report Anthrax Vaccines & Therapeutics as of June 2013 provides a competitor analysis in the development pipelines of novel vaccines and therapeutics for prophylaxis of Bacillus anthracis infection and treatment of anthrax. Purchase of the pdf report includes a 6-month online ...

... and their competitive position assessed in light of the key success factors. Sources of information are LMP’s proprietary database, scientific literature (abstracts, ... of each major player in the field Downoad Sample Pages: Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: A ...

Competitive Information Service Package – 1-year subscription: Flat-Rate Access to La Merie Publishing Reports R&D Drug Pipeline Database R&D Pipeline News Subscription to this product provides access during one year to three Competitive Intelligence information products released by La Merie ...

The Competitive Intelligence Report Coagulation Factors provides a competitor analysis of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of May 2013. Purchase of the pdf report includes a 6-month online access ...

The Competitive Intelligence Report Thrombolytics & Fibrinolytics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel thrombolytics and fibrinolytics for treatment of cardiovascular thrombosis, stroke and eye diseases. Purchase of the pdf report includes ...

The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated ...

The Competitive Intelligence Report Human Papilloma Virus (HPV) Vaccines & Therapeutics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel vaccines and therapeutics for prophylaxis of HPV infection and HPV-induced neoplasias and treatment of HPV-induced ...

Product description The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the ...

Product description The Competitive Intelligence Report Human Growth Hormone (hGH) as of April 2013 provides a competitor analysis in the development pipeline of biosimilar versions of somatropin and next generation biobetter/biosuperior hGH products for treatment of growth hormone deficiency (GHD) in ...

... and development. In addition, the report lists company-specific product portfolios and R&D pipelines of Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) on the market or in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of ...

Product description The Competitive Intelligence Report Insulin as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant insulin and in...

Product description The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural...

How do antibody characteristics impact clinical success? The analytical report 'Influence of Antibody Attributes on Clinical Success – A Technology and Coporate Benchmark Analysis' evaluates the impact of a number of antibody attributes on the success rate of antibodies in clinical development. Among ...

... legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to ... the different in vitro and in antibody generation technologies. Attrition rate was defined as the percentage of failed antibodies of all active and inactive ...

... (ART) as of February 2013 provides a competitor analysis in the development pipeline of novel recombinant and purified FSH, hCG and LH receptor agonists for ... , the report lists company-specific R&D pipelines of FSH, LH and hCG products and projects. Competitor projects are listed in a tabular format providing ...

... Intelligence Report Enzyme Replacement & Enhancement Therapies (ERT) as of January 2013 provides a competitor analysis in the development pipeline of novel enzyme replacement therapies and of enzyme enhancement therapies to treat human genetic diseases/lysosomal storage diseases and exocrine pancreatic ...

... infect humans. HSV-1 and HSV-2 cause the viral disease herpes simplex which can be categorized into one of several distinct disorders ... . In addition, the report lists company-specific R&D pipelines of Herpes Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information ...

... description The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists & Antagonists provides a competitor analysis in the development pipeline of novel small ... with the project data to print or export an individual report. Toll-like receptors (TLRs) are a class of proteins that play a key role ...

... next couple of years and are paving the way for biosimilar antibodies. The first Avastin biosimilars are already in clinical trials and ... diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...

... Inhibitors and IL-6 Receptor (IL-6R) Antagonists for treatment of rheumatoid arthritis and multiple myeloma provides a competitor evaluation in the field of R&D projects with Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists as of October 2012. Purchase of the downloadable pdf report ...

... , Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, ...

... targeting Mycobacterium tuberculosis for prophylaxis and treatment of tuberculosis. In addition, the report lists corporate and public R&D pipelines of Tuberculosis Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action ...

... description The present Competitive Intelligence Report about Malaria Vaccines & Therapeutics provides a competitor evaluation in the field of investigational small molecules and ... regions. Each year more than 350 million new cases of Malaria occur, it is one of the world’s most common diseases. People with ...